These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Usefulness of the CHA Jaakkola S; Kiviniemi TO; Nuotio I; Hartikainen J; Mustonen P; Palomäki A; Jaakkola J; Ylitalo A; Hartikainen P; Airaksinen KEJ Am J Cardiol; 2018 May; 121(10):1182-1186. PubMed ID: 29526276 [TBL] [Abstract][Full Text] [Related]
6. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Hart RG; Diener HC; Yang S; Connolly SJ; Wallentin L; Reilly PA; Ezekowitz MD; Yusuf S Stroke; 2012 Jun; 43(6):1511-7. PubMed ID: 22492518 [TBL] [Abstract][Full Text] [Related]
7. Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation with warfarin or edoxaban: An in-depth analysis from the ENGAGE AF-TIMI 48 randomized trial. Nelson SE; Giugliano RP; Antman EM; Park JG; Norden AD; Rost NS; Silverman S; Singhal AB; Lanz HJ; Braunwald E; Ruff CT; J Clin Neurosci; 2021 Apr; 86():294-300. PubMed ID: 33446422 [TBL] [Abstract][Full Text] [Related]
8. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Fang MC; Chang Y; Hylek EM; Rosand J; Greenberg SM; Go AS; Singer DE Ann Intern Med; 2004 Nov; 141(10):745-52. PubMed ID: 15545674 [TBL] [Abstract][Full Text] [Related]
9. Comparison of the CHA Yao X; Gersh BJ; Sangaralingham LR; Kent DM; Shah ND; Abraham NS; Noseworthy PA Am J Cardiol; 2017 Nov; 120(9):1549-1556. PubMed ID: 28844514 [TBL] [Abstract][Full Text] [Related]
10. Utility of HAS-BLED and CHA Ward R; Ponamgi S; DeSimone CV; English S; Hodge DO; Slusser JP; Graff-Radford J; Rabinstein AA; Asirvatham SJ; Holmes D Mayo Clin Proc; 2020 Oct; 95(10):2090-2098. PubMed ID: 32829908 [TBL] [Abstract][Full Text] [Related]
11. Association of Ischemic Stroke, Major Bleeding, and Other Adverse Events With Warfarin Use vs Non-vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation With a History of Intracranial Hemorrhage. Tsai CT; Liao JN; Chiang CE; Lin YJ; Chang SL; Lo LW; Hu YF; Tuan TC; Chung FP; Chao TF; Lip GYH; Chen SA JAMA Netw Open; 2020 Jun; 3(6):e206424. PubMed ID: 32478848 [TBL] [Abstract][Full Text] [Related]
12. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Fang MC; Go AS; Chang Y; Hylek EM; Henault LE; Jensvold NG; Singer DE Am J Med; 2007 Aug; 120(8):700-5. PubMed ID: 17679129 [TBL] [Abstract][Full Text] [Related]
13. Traumatic head injury in the anticoagulated elderly patient: a lethal combination. Karni A; Holtzman R; Bass T; Zorman G; Carter L; Rodriguez L; Bennett-Shipman VJ; Lottenberg L Am Surg; 2001 Nov; 67(11):1098-100. PubMed ID: 11730229 [TBL] [Abstract][Full Text] [Related]
14. Comparison of the CHADS2, CHA2DS2-VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: the AMADEUS trial. Apostolakis S; Lane DA; Buller H; Lip GY Thromb Haemost; 2013 Nov; 110(5):1074-9. PubMed ID: 24048467 [TBL] [Abstract][Full Text] [Related]
15. Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study. Apostolakis S; Lane DA; Guo Y; Buller H; Lip GY J Am Coll Cardiol; 2012 Aug; 60(9):861-7. PubMed ID: 22858389 [TBL] [Abstract][Full Text] [Related]
16. Relation of Stroke and Bleeding Risk Profiles to Efficacy and Safety of Edoxaban for Cardioversion of Atrial Fibrillation (from the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation [ENSURE-AF] Study). Lip GYH; Merino JL; Dan GA; Themistoclakis S; Ellenbogen KA; De Caterina R; Goudev A; Jin J; Melino M; Winters SM; Goette A Am J Cardiol; 2018 Jan; 121(2):193-198. PubMed ID: 29169605 [TBL] [Abstract][Full Text] [Related]
17. Time in Therapeutic Range and Percentage of International Normalized Ratio in the Therapeutic Range as a Measure of Quality of Anticoagulation Control in Patients With Atrial Fibrillation. Chan PH; Li WH; Hai JJ; Chan EW; Wong IC; Tse HF; Lip GY; Siu CW Can J Cardiol; 2016 Oct; 32(10):1247.e23-1247.e28. PubMed ID: 26927855 [TBL] [Abstract][Full Text] [Related]
18. Prediction of long-term net clinical outcomes using the TIMI-AF score: Comparison with CHA Rivera-Caravaca JM; Roldán V; Esteve-Pastor MA; Valdés M; Vicente V; Marín F; Lip GYH Am Heart J; 2018 Mar; 197():27-34. PubMed ID: 29447781 [TBL] [Abstract][Full Text] [Related]
19. Stroke prevention using dabigatran in elderly Chinese patients with atrial fibrillation. Chan PH; Huang D; Hai JJ; Li WH; Yin LX; Chan EW; Wong IC; Lau CP; Chiang CE; Zhu J; Tse HF; Siu CW Heart Rhythm; 2016 Feb; 13(2):366-73. PubMed ID: 26392326 [TBL] [Abstract][Full Text] [Related]
20. Ischemic Stroke and Bleeding: Clinical Benefit of Anticoagulation in Atrial Fibrillation After Intracerebral Hemorrhage. Stanton RJ; Eckman MH; Woo D; Moomaw CJ; Haverbusch M; Flaherty ML; Kleindorfer DO Stroke; 2020 Mar; 51(3):808-814. PubMed ID: 32000590 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]